In addition, we also observed that in patients with EGFR activating mutation(s), the survival time was longer in the low- than in the high-SHCBP1 expression group, and was similar to that in the non-EGFR activating mutation group, clinically supporting the notion that SHCBP1 played an important role in EGF-mediated NSCLC malignancy. This evidence concerns the gene SHCBP1 and non-small cell lung carcinoma.